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Abstract   
Proteasome inhibitors have been shown to increase adeno-associated virus (AAV)-
mediated transduction in vitro and in vivo. To assess if proteasome inhibitors also 
increase lipid-mediated gene transfer with relevance to cystic fibrosis (CF), we first 
assessed the effects of doxorubicin and N-acetyl-L-leucinyl-L-leucinal-L-norleucinal  
in non-CF (A549) and CF (CFTE29o-) airway epithelial cell lines. CFTE29o- cells 
did not show a response to Dox or LLnL; however, gene transfer in A549 cells 
increased in a dose-related fashion (p<0.05), up to approximately 20-fold respectively 
at the optimal dose (no treatment: 9.3x104 ± 1.5x103, Dox: 1.6x106 ± 2.6x105, LLnL: 
1.9x106 ± 3.2x105 RLU/mg protein). As Dox is used clinically in cancer 
chemotherapy we next assessed the effect of this drug on non-viral lung gene transfer 
in vivo. CF knockout mice were injected intraperitoneally (IP) with Dox (25 to 100 
mg/kg) immediately before nebulisation with plasmid DNA carrying a luciferase 
reporter gene under the control of a CMV promoter/enhancer (pCIKlux) complexed to 
the cationic lipid GL67A. Dox also significantly (p<0.05) increased expression of a 
plasmid regulated by an elongation factor 1α promoter (hCEFI) approximately 8-fold. 
Although administration of Dox before lung gene transfer may not be a clinically 
viable option, understanding how Dox increases lung gene expression may help to 
shed light on intracellular bottle-necks to gene transfer, and may help to identify other 
adjuncts that may be more appropriate for use in man. 
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Introduction 
Proteasome inhibitors have been shown to increase adeno-associated virus (AAV)-
mediated transduction in vitro and in vivo (1-3).  The exact mechanism remains 
unclear and does not appear to be related solely to the inhibition of vector degradation 
through the ubiquitin-proteasome degradation pathway. In contrast to viral 
transductions, the pathways involved in cell and nuclear entry of non-viral gene 
transfer agents, and movement of these complexes within the cell, are poorly 
understood and the contribution (if any) of proteasomes to this process remains 
unclear. Two studies have reported that proteasome inhibitors increased non-viral 
gene transfer in vitro (4;5). 
 
CF is a chronic disease which will require treatment with gene transfer agents over the 
life-time of the patient. Problems associated with repeat administration of most viral 
vectors have been well described (6;7).  Because of this, repeat administration of non-
viral gene transfer agents is currently the most promising approach for the 
development of cystic fibrosis (CF) gene therapy. The cationic lipid GL67A (8) is, in 
our hands, the most efficient non-viral vector for lung transfections. GL67A consists 
of three components: (1) the cationic lipid GL67 [Cholest-5-en-3-ol (3β)-,3-[(3-
aminopropyl)[4-[(3-aminopropyl)amino]butyl]carbamate], consisting of an amine 
(spermine) and a lipid (cholesterol) component linked together via a carbamate linker, 
(2) DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) a naturally occurring 
neutral lipid, (3) DMPE-PEG5000 (1,2-Dimyristoyl-sn-Glycero-3-
Phosphoethanolamine-N-[methoxy (Polyethyleneglycol)5000] which is 1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine linked to polyethylene glycol 
monomethylether (average molecular weight ca. 5000) via a carbamate linkage. To 
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generate the gene transfer agent the three lipids are formulated at 1:2:0.05 
(GL67:DOPE:DMPE-PEG5000) molar ratios and complexed to DNA (8). We have 
achieved partial correction of the chloride transport defect in the lungs of CF patients 
after GL67A-mediated gene transfer of plasmid DNA carrying the cystic fibrosis 
transmembrane conductance regulator (CFTR) cDNA (9).  However, the efficiency of 
non-viral gene transfer is comparatively low compared to viral vectors, such as for 
example Sendai virus (10), and it is currently unclear, if non-viral gene therapy can 
ameliorate the chronic lung infection and inflammation that causes most morbidity 
and mortality in CF subjects. The clinical trial programme currently carried out by the 
UK CF Gene Therapy Consortium (www.cfgenetherapy.org.uk) aims to assess if 
GL67A-mediated CFTR gene transfer is able to ameliorate of CF lung disease. In 
parallel, however, we are investigating a variety of adjuncts that may further increase 
GL67A-mediated lung gene transfer as part of our pre-clinical development 
programme.   
 
Here, we assessed if proteasome inhibitors could improve GL67A-mediated gene 
transfer in the mouse lung. Doxorubicin, an anthracyclin derivative, and N-acetyl-L-
leucinyl-L-leucinal-L-norleucinal (LLnL), a tripeptide aldehyde inhibitor, have 
previously been shown to increase AAV-mediated gene transfer in vitro (11).  
Importantly, doxorubicin is in clinical use for cancer chemotherapy, and in support of 
our translational research programme, we chose this drug to determine, if proteasome 
inhibition increases non-viral gene transfer in the mouse lung in vivo. 
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Materials and Methods  
In vitro transfection 
A549 cells, an adenocarcinoma cell line (ATCC, Manassas, USA) and a cystic 
fibrosis tracheal epithelial cell line (CFTE29o-) (12) were plated onto 6-well plates 
(100,000 cells/ well). Approximately 24 hr later cells were transfected with the 
eukaryotic expression plasmids pCIKLux carrying a luciferase reporter gene under the 
control of the cytomegalovirus (CMV) immediate/early promoter (1 μg DNA/well) or 
an irrelevant control plasmid carrying no reporter gene (pCIK-empty). Each was 
complexed to Lipofectamine 2000 (LF2000, Invitrogen, Paisley, UK) according to 
manufacturers recommendations for 6 hr. During this time cells were also exposed to 
various concentrations of doxorubicin (0.5-20 mM, Sigma-Aldrich, Poole, UK) 
dissolved in sterile water for injection or N-acetyl-L-leucinyl-L-leucinal-L-norleucinal 
(LLnL: 10-100 μM, Sigma-Aldrich) dissolved in ethanol. After 6 hr the medium was 
removed and replaced with fresh MEM medium containing 10% FCS and 1% 
ampicillin/streptomycin. Cells were harvested 48 hr after transfection and 
resuspended in 500 μl 1xRLB buffer (Promega, Southampton, UK) followed by three 
freeze/thaw cycles and centrifugation at 13,000 gav for 10 min. The supernatant was 
frozen for quantification of luciferase expression.  
 
Mice 
Male and female C57Bl/6, Balb/C mice (Charles River, UK) or gut-corrected CF-
knockout mice on a mixed genetic background (13) (bred in-house) were used at 
approximately 6-12 weeks of age (for details see Figure legends). All experiments 
were carried out with approval of the appropriate local Ethics Committee and 
according to Home Office regulations. 
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Doxorubicin administration in vivo 
Doxorubicin (Dox, Sigma Aldrich, Poole, UK) was dissolved in sterile water for 
injection to 5 mg/ml and administered intraperitoneally (IP) (0-100 mg/kg) 
immediately before gene transfer. IP injection of proteasome inhibitors has previously 
been shown to be effective in the context of AAV-mediated gene transfer. In some 
experiments Dox was administered topically to the lung using our standard “nasal 
sniffing” protocol. For this the mice were anaesthetised with isofluorane and a single 
100 µl bolus containing 125 to 500 μg Dox (equivalent to 6 to 25 mg/kg) was applied 
to the nose and rapidly sniffed into the lung. 25 mg/kg was the highest dose feasible 
for topical administration as mice showed signs toxicity above this concentration. 
Caelyx® (2 mg/ml), a pegylated liposome encapsulated Dox formulation, was injected 
IP or intravenously (IV) immediately before gene transfer.  
 
In vivo transfection of murine lung  
The cationic lipid GL67A is a mixture of GL67 (Genzyme, Haverhill, UK), DOPE 
and DMPE-PEG5000 (Avanti Lipids, Alabama, USA) (8).  The lipids were 
formulated and freeze-dried by OctoPlus N.V. (Leiden, The Netherlands) as 
previously described (8).  pCIKLux or pG4-hCEFI-soLux, which is an advanced 
fourth generation plasmid carrying a CpG-depleted, codon optimised luciferase 
reporter gene regulated by a hybrid promoter consisting of the CMV enhancer and the 
elongation factor 1α promoter (14). 
 
Nebulisation: Immediately after Dox administration mice were placed into an 
exposure chamber and exposed to an aerosol generated by a PARI LC+ nebuliser 
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(PARI GmbH, Starnberg, Germany) at a pressure of 22 psi for 1 hr. GL67A/pDNA 
complexes for aerosolisation were prepared as previously described (14).  Briefly, 25 
mg plasmid DNA (5 mg/ml)  were complexed with 5 ml GL67A to a final molar ratio 
of 6:8 in a total volume of 10 ml. Reporter gene expression was quantified 24 hr after 
transfection to detect maximal levels of gene expression. 
 
Bioluminescence imaging 
D-Luciferin (Xenogen Corporation, Alameda, CA) was either administered IP (150 
mg/kg in 200 μl) or topically (75 mg/kg in 100 μl), using our “nasal sniffing” protocol 
described above, to mice 10 min before imaging.  Bioluminescence (photons s-1 cm-2 
sr-1) from living mice was measured using an IVIS50 system (Xenogen Corporation, 
Alameda, CA, USA) at a binning of 4, over 10 minutes, using the software 
programme Living Image (Xenogen). For anatomical localisation a pseudocolour 
image representing light intensity (blue least intense, red most intense) was generated 
using Living Image software and superimposed over the greyscale reference image. 
To quantify bioluminescence in the nose and right and left lungs photon emission in a 
defined area was measured by marking a standardized area for quantification.  
 
Tissue homogenate-based luciferase assay 
 Mice were culled by cervical dislocation. The mouse lungs were harvested and frozen 
in liquid nitrogen.  To extract luciferase protein lungs were placed in 100 μl and 300 
μl 1xRLB buffer (Promega), respectively. The lung was homogenized using a Fast-
Prep homogenizer (Thermo Fisher Scientific, Waltham, MA, USA) set to 40 m/sec for 
45 seconds followed by 15 min incubation at room temperature. The supernatant was 
removed and transferred to a QiaShredder column (Qiagen, Crawley, Sussex) and 
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centrifuged (1 min at 16,000gav) followed by an additional centrifugation (5 min at 
16,000gav). Luciferase activity was measured in the supernatant using a standard 
luciferase assay kit (Promega) and the TD-20e luminometer (Turner, Sunnyvale, CA, 
USA). Total protein per sample was determined using the BioRad protein assay kit 
(BioRad laboratories, Hercules, CA) and luciferase activity was expressed as arbitrary 
relative light units (RLU)/mg total protein.  
 
Statistical analysis 
Statistical analyses were performed by ANOVA and Kruskal-Wallis followed by 
post-hoc analysis appropriate for parametric and non-parametric data. The null 
hypothesis was rejected at p<0.05. 
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Results 
Proteasome inhibitors in vitro  
To establish proof-of-principle, we first assessed the effects of proteasome inhibitors 
on Lipofectamine 2000-mediated (LF2000) gene transfer in two airway epithelial cell 
lines (A549 and CFTE29o-  cells). Cells were exposed to various concentrations of 
Dox (0.5-20 mM) and LLnL (10-100 μM) for 6 hr during transfection with pCIKLux 
complexed to LF2000. CFTE29o-  cells did not show a response to Dox or LLnL 
(data not shown), but gene transfer in A549 cells increased in a dose-related fashion 
approximately 20-fold respectively, at the optimal dose (p<0.05, n=8/group) (Fig 1). 
We reproducibly observed a U-shaped dose-response with Dox. 
 
Doxorubicin effects in the murine lung  
To assess the effect of proteasome inhibitors on non-viral lung gene transfer in vivo 
CF knockout mice were injected intraperitoneally (IP) with Dox (0, 25, 50 and 100 
mg/kg, n=8 mice/group) immediately before nebulisation of pCIKlux complexed to 
the cationic lipid GL67A, and compared to animals transfected without Dox. CF 
knockout mice were used because we routinely use these for gene transfer studies and 
have a large in house breeding colony. Gene expression was analysed 24 hr after gene 
transfer. Dox increased gene transfer in a dose-related fashion (Fig 2). Mice receiving 
the lowest dose (25 mg/kg) did not show an increase in luciferase expression, but in 
mice receiving 50 or 100 mg/kg luciferase was significantly (approximately 20-fold, 
p<0.05) increased compared to no Dox administration. Administration of 100 mg/kg 
did not increase gene transfer compared to 50 mg/kg, but toxicity was observed at this 
dose, with 1 out of 8 mice dying within the 24 hr period and 4 out of 7 mice showing 
hunching and pilo-erection. In contrast all mice treated with 50 mg/kg dose were 
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outwardly indistinguishable from mice not treated with Dox. Subsequent experiments 
were, therefore, carried out with a dose of 50 mg/kg.   
 
To assess reproducibility of the results the experiment was repeated using the optimal 
dose of 50 mg/kg Dox I.P. with higher n numbers showing reproducible results (Fig 
3). Although we would not expect there to be difference between CF and non-CF 
mice, we also assessed the effects of Dox in wild-type Balb/C and C57Bl/6 mice and 
consistently demonstrated a significant (p<0.05) increase in GL67A-mediated lung 
gene expression after IP Dox administration, respectively (Fig 3). 
 
Since the optimal dose (50 mg/kg) is approximately 3 times higher than that used 
clinically, we attempted to increase the local concentration of Dox in the lung by 
administering the drug (6 to 25 mg/kg) topically via nasal sniffing. However, this did 
not increase luciferase expression compared to mice receiving no Dox (data not 
shown).  
 
In vivo bioluminescence imaging  
We have previously shown that cationic lipid GL67A-mediated luciferase gene 
transfer can be detected with in vivo bioluminescence imaging (BLI) in lungs of mice 
following nasal “sniffing” of lipid/DNA complexes into the lung (15).  However, 
nebulisation is generally less efficient than nasal “sniffing” and, as shown here, 
insufficient (only 2 out of 9 mice showed a weak signal) to allow BLI using standard 
I.P administration of the luciferin substrate (150 mg/kg) (Fig. 4a). Interestingly, we 
showed that (a) a significantly (p<0.001) stronger BLI signal can be visualised in 7 
out of 9 mice after GL67A/pCIkLux nebulisation by administering the luciferin 
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substrate topically (75 mg/kg) to the lungs of Balb/C mice by “nasal sniffing” instead 
of using the standard IP route (Fig. 4b) despite the fact that only half of  the I.P dose 
was administered and that (b) IP administration of Dox (50 mg/kg) further 
significantly (p<0.05) increased the BLI signal (Figs 4c+d).  
 
Promoter-independent increase in gene expression  
In addition to the pCIKLux plasmid which is regulated by the immediate/early 
cytomegalovirus (CMV) promoter/enhancer, we also assessed the effects of Dox on a 
eukaryotic luciferase expression plasmid regulated by a hybrid promoter consisting of 
the CMV enhancer and the elongation factor 1α promoter (pG4-hCEFI-soLux). 
Similar to results obtained with pCIKLux, Dox significantly (p<0.005) increased 
pG4-hCEFI-soLux -mediated expression in Balb/C mice (Fig 5).  
 
Effects of Caelyx® on lung gene expression  
The most advanced Dox formulation currently in clinical use is a pegylated liposome 
encapsulated formulation [Caelyx® (UK) or Doxil® (USA)]. We, therefore, assessed 
the effects of Caelyx® on GL67A/pCIKLux-mediated lung gene transfer. We 
administered either 4, 16.5 or 40 mg/kg I.P to CF knockout mice (n=8/group) mice. 
These doses were chosen because 16.5 mg/kg is equivalent to 50 mg/m2 body surface, 
the latter being dose used in man, and 40 mg/kg being equivalent to 400 μl of a 2 
mg/ml solution, the maximum volume allowed for IP injection under Home Office 
license regulations. All mice tolerated the treatment well and were culled 24 hr after 
gene transfer. IP administration of Caelyx® did not increase reporter gene expression 
in the lung (Fig 6a).  
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For clinical use Caelyx® is administered intravenously (IV) and we, therefore, also 
assessed the effects of IV administration on lung gene expression. Caelyx® (4 or 20 
mg/kg) was injected into the tail vein of mice immediately before nebulisation of 
GL67A/pCIKlux. The 20 mg/kg, equivalent to 200 μl of a 2 mg/ml solution, is the 
maximum volume allowed for IV injection under Home Office license regulations. 
All mice tolerated the treatment well and were culled 24 hr after gene transfer. IV 
injection of Caelyx® modestly increased gene expression, but this did not reach 
significance (p=0.05) (Fig 6b). 
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Discussion 
Here, we show that proteasome inhibitors increase cationic lipid-mediated gene 
transfer in vitro and in murine lung in vivo. However, the clinically relevant agent 
doxorubicin shows a narrow efficacy-toxicity window, which was not improved by 
variations in route of administration. We conclude, it is unlikely that Dox will be 
suitable for clinically relevant gene therapy in CF patients.  
 
Proteasome inhibitors have been shown to increase AAV-mediated gene transfer in 
various ex vivo and in vivo models of lung gene transfer, including air liquid 
interphase cultures, xenograft models and the murine lung (3;11).  However, the 
mechanism is unclear; possibilities including (a) prevention of virus degradation, (b) 
improved nuclear uptake, (c) improved genome uncoating, (d) enhanced capsid 
processing, (e) improved second strand synthesis and (e) reduced degradation of the 
recombinant protein. The effect of proteasome inhibitors in the context of non-viral 
gene transfer has, to the best of our knowledge, only been described in two in vitro 
studies. Kim J et al reported that proteasome inhibitors increased non-viral peptide-
mediated gene transfer and Kim KI et al showed that doxorubicin increases lipid-
mediated gene transfer (4;5). 
 
In our hands the benefits of LLnL and doxorubicin on non-viral gene transfer in vitro 
were cell type specific. Although A549 cells, an adenocarcinoma cell line with type II 
cell characteristics responded to both proteasome inhibitors with a 20-30 fold increase 
in gene expression, the drugs did not increase gene expression in CFTE29o-  cells, 
derived from tracheal epithelium of a CF subject. In the context of AAV transduction 
A549 cells also responded to LLnL and doxorubicin (11) whereas as shown by Kim et 
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al (4) proteasome inhibitors did not increase LF2000-mediated gene transfer in CF/T1 
cells, another CF airway epithelial cell line. Similarly Yan et al showed that the 
response to LLnL varies in different airway cell lines when transduced with AAV 
(11).  It is unlikely that the unresponsiveness of CFTE29o- cells to proteasome 
inhibitors is due to the CF genotype of these cells, because we also demonstrated that 
non-viral gene transfer in both CF-knockout mice and non-CF mice responded 
similarly to Dox pre-treatment.  
 
Although doxorubicin treatment increased non-viral gene transfer by up to 20-fold 
these levels in our experience are still too low to allow detection of recombinant 
protein with immunohistochemistry or X-gal-based methods. Thus, we are currently 
unable to determine which cells have been transduced and if the number of cells 
expressing the recombinant protein, or the amount of protein per cell, increased in 
response to doxorubicin treatment. This question is also difficult to address in the 
existing AAV studies. Although the number of reporter gene expressing cells 
increased in response to proteasome inhibition, it is unclear if negative cells were 
untransduced, or if cells were transduced but levels of reporter gene expression were 
below the detection limit of the assay (2).  Kim et al suggested that proteasome 
inhibition did not affect the number of cells transfected with peptide-based gene 
transfer agents, but increased the amount of protein made per cell (4). 
 
Proteasome inhibitors have been shown to increase AAV-mediated transduction in 
C57Bl/6 mice and Rag-deficient mice (2;11).  Here, we show that proteasome 
inhibitors increase lipid-mediated gene transfer in a variety of strains including wild 
type Balb/C mice, C57Bl/6 mice and gut-corrected CF knockout mice on a mixed 
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genetic background. Thus, the drug action appears to be strain- and CF genotype 
independent. By spiking homogenized lung tissue with Dox immediately before 
performing a luciferase assay we excluded a direct effect of the drug on photon 
emission (data not shown). 
 
We also show that Dox pretreatment improved in vivo bioluminescence imaging 
(BLI) of reporter gene expression after nebulisation of GL67A/DNA complexes to the 
mouse lung. The whole body nebulisation set-up used in the study is comparatively 
inefficient in delivering gene transfer agents to the murine lung and it was, therefore, 
not surprising that photon emission was too low to generate a visible BLI signal in 
most animals after IP injection of luciferin substrate. Importantly, however, topical 
administration of luciferin directly to the lung increased photon emission significantly 
and generated a BLI signal in 7 out of 9 mice despite the fact that only half of the dose 
recommended for IP injections was delivered. Not surprisingly a combination of 
luciferin administration directly to the lung and doxorubicin pre-treatment further 
increased photon emission. The enhanced photon emission after topical administration 
of luciferin is likely due to a higher local concentration of the substrate in transfected 
lung epithelium. Buckley et al have shown that topical administration of luciferin also 
increased lung photon emission after virus-mediated gene transfer (16).  More 
extensive dose-optimisation may significantly reduce the amount of luciferin required 
and, thereby, reduce costs of BLI studies.  
 
Although it is generally assumed and probably most plausible that the beneficial 
effects of doxorubicin on viral and non-viral gene transfer are due to proteasome 
inhibition, it is worth mentioning that doxorubicin has additional effect. The drug 
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intercalates into DNA and inhibits topisomerase II activity (17) and the implications 
of these actions on gene expression after gene transfer are not understood. 
Importantly, we show that the drug action is promoter/enhancer-independent as 
doxorubicin increased CMV and elongation factor 1α (hCEFI)-dependent gene 
expression. Doxorubicin is also known to activate reactive oxygen species (ROS) and 
one conceivable explanation may be that ROS activate the transcription factor 
NFκB.(18;19) 
 
A more advanced pegylated liposomal formulation of the first-generation doxorubicin 
is currently in clinical use. The coating prolongs the circulating half-life and slows 
down plasma clearance compared to free doxorubicin, but most importantly leads to 
preferential accumulation in tumors, thereby reducing systemic toxicity (20) 
respectively. We also assessed the effects of Caelyx® IP administration on airway 
gene transfer, but did not detect any changes in gene expression. Clinically Caelyx® is 
administered intravenously and, therefore, we assessed its effects via this route of 
delivery. Although there was a modest increase in lung gene expression, this did not 
reach significance. These results are perhaps unsurprising given that the formulation 
was developed for accumulation in tumours. Caelyx® liposomes have an average 
diameter of approximately 100 nm able to penetrate the discontinuous endothelium of 
tumour vasculature, but not other tissues (21).  Thus, the drug may not have reached 
the airway epithelium in sufficiently high concentrations. In contrast Yan et al showed 
that IV administration of Doxil® , a formulation identical to Caelyx®, increased AAV-
mediated gene expression in a murine tracheal xenograft model (11).  The newly 
formed vasculature supplying the xenograft may be more discontinuous than the 
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vasculature in the in vivo lung, thereby allowing for drug delivery to the target 
epithelium.  
 
Conclusions 
As for AAV-mediated gene transfer, doxorubicin increased lipid-mediated gene 
transfer to the murine lung. The clinically relevant agent doxorubicin shows a narrow 
efficacy-toxicity window, which was not improved by variations in route of 
administration. We conclude that although it may be unlikely that Dox will be suitable 
for clinically relevant gene therapy in CF patients an understanding on how the drug 
increases lung gene expression may help to shed light on intracellular bottle-necks to 
gene transfer, and may help to identify other adjuncts which may be more appropriate 
for use in humans.   
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